Clinical Study
A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer
Table 1
Patient demographics and baseline clinical characteristics.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The percentages are calculated out of the total survey’s cohort of 195 patients. Totals are occasionally above 195 due to multiple reporting for example initial pathology type and number of metastases. ECOG: Eastern cooperative oncology group; CEA: carcinoembryonic antigen; CA: cancer antigen. *Including infiltrated lymph around veins, moderate to poor differentiated, nonspecified. Laboratory tests included full blood count, liver function test, and urea and electrolytes, of which only a few are listed here. “Single” agents included 5-FU, fluroblastin, or Xeloda; “Mayo” included 5-FU and leucovorin or 5-FU and Rescuvolin or ABIC fluorouracil and Isovorin; “Other” included FOLFIRI, FOLFIRI with bevacizumab, FOLFIRI followed by Capecitabine, XELOX, and FOLFIRI with mitomycin, Tomudex, and capecitabine. Of those patients who received chemotherapy for colorectal cancer prior to this study, 28 (74%) patients received the chemotherapy in the adjuvant setting. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||